Latest Information Update: 25 Mar 2017
At a glance
- Originator Takeda
- Class Neuroprotectants
- Mechanism of Action Cell differentiation modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 21 May 2010 Discontinued - Phase-I for Stroke in Japan (Parenteral)
- 31 Dec 2008 Phase-I clinical trials in Stroke in Japan (Parenteral)